As the U.S. economy takes significant steps to lessen pandemic restrictions, the need for testing may still be an integral part of early detection and risk management for the foreseeable future. At least, that is what RAM Global is hoping for as the company positions itself as a high-volume and rapid, low-cost testing solution for COVID-19 and future viruses.
But what makes RAM Global’s testing solution unique?
RAM engineered a terahertz express analyzer diagnostic platform designed to detect any pathogen through a swab-based test, including COVID-19.
The science behind the RAM solution is that every pathogen has a unique frequency identified through medical research and placed into RAM’s algorithmic models. Thus, ideally, the innovative platform can accurately test current and new pathogens without extensive lead times that other costly testing solutions require.
RAM’s proprietary sensor technology offers a fundamentally transformative method of collecting, understanding, and distributing data via an optional cloud-based platform that offers real-time data sharing between healthcare professionals and government agencies to make informed decisions to protect the public. In addition, the comprehensive testing infrastructure, and reporting can help remove issues that can lead to inaccuracies.
And RAM’s in-vitro diagnostic testing rivals premium gold standard Polymerase Chain Reaction (PCR) tests on the market but provides better accuracy, takes less time to procure results, and is cost-effective. However, the company is also developing an enhanced pathogen testing method to complement its high-tech analyzer that will take your breath away, literally.
To explain the practical use of its developing technology in layman’s terms, it is similar to an alcohol breathalyzer test. First, a person breathes into a patented plastic device called a breathalyzer. Then, the breathalyzer is placed into a terahertz express analyzer that will provide accurate results in under two minutes. This method of testing can avoid swab testing methods that some may find intrusive or uncomfortable.
As the company enters a final round of testing with live samples before seeking FDA approval, corporations, entertainment industries, and small businesses are poised to open up. First, however, they will need an ongoing, highly cost-effective testing solution that can provide assurances to the public to mitigating the risks and negative perceptions of superspreader events.
RAM has already received the European Union's mandatory conformity CE marking for regulating the goods sold within the European Economic Area (EEA). Additionally, RAM received clearance from the United Arab Emirates’ Ministry of Health and Prevention (MOHAP). Both of these accomplishments are laying the global groundwork to help governments abroad.
And the promising news about RAM’s technology is spreading fast. XPrize held a 6-month competition with a $6 million purse for rapid SARS-CoV-2 testing for companies with a faster, cheaper, and scalable solution. RAM Global was one of four recipients in the open innovation track and was recognized with the distinguished XPrize award in March 2021.
When the FDA greenlights RAM’s in vitro diagnostic platform, the U.S. government, health professionals, and corporations may avoid the loss of time and life amid the threat of future pathogens. Because implementing a standardized enterprise system that is non-intrusive, rapid, accurate, and cost-effective can already be in place.
